31 Mar 2022
Assets59.15
Total Income14.63
Profit After Tax0.99
NET Worth36.59
Reserves and Surplus25.37
Total Borrowing14.21
At a glance
Updated 2026-08-24The shares listed at ₹600.00, a 53.45% move from the issue price. Senores Pharmaceuticals is a Mainboard IPO with an issue size of ₹582.11 crore, proposed for listing on BSE, NSE. The offer opens on 20th Dec 2024 and closes on 24th Dec 2024. The issue structure includes a fresh issue of ₹500.00 crore and an offer-for-sale component of ₹82.11 crore. The current listing schedule points to 30th Dec 2024.
Issue details
Listing atBSE, NSE
Issue typeBook Build Issue
Issue size₹582.11 Cr
Fresh issue₹500.00 Cr
Offer for sale₹82.11 Cr
Face value₹10
Price band₹372.00–₹391.00
Allotment26th Dec 2024
Listing30th Dec 2024
Listing performance
Full performance ↗Issue price₹391.00
Listing price₹600.00
Current price—
Listing gain53.45%
Current return—
Price progressionIssue → Listing → Current
Grey market
GMP page ↗Latest GMP₹284.00
GMP / upper price72.63%
Est. listing₹675.00
GMP is unofficial sentiment data, not an exchange price.
Timeline
Opens20th Dec 2024
Closes24th Dec 2024
Allotment26th Dec 2024
Refund27th Dec 2024
Demat27th Dec 2024
Listing30th Dec 2024
Subscription demand
Full bidding ↗Total97.86×
Lot size
| Investor | Lots | Shares | Amount |
|---|---|---|---|
| Minimum Bid | 1 | 38 | ₹14,858 |
Company
Use of proceeds
| Object | Amount |
|---|---|
| Investment in one of the Subsidiaries, Havix, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility | ₹107.00 Cr |
| Re-payment/pre-payment, in full or in part, of certain borrowings availed by the Company | ₹73.48 Cr |
| Investment in our Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiaries | ₹20.22 Cr |
| Funding the working capital requirements of the Company | ₹43.26 Cr |
| Investment in the Subsidiaries, namely, SPI and Ratnatris to fund their working capital requirements | ₹59.48 Cr |
| Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes | ₹154.37 Cr |
Financials
Full financials ↗31 Mar 2023
Assets131.05
Total Income39.02
Profit After Tax8.43
NET Worth45.50
Reserves and Surplus35.25
Total Borrowing60.76
31 Mar 2024
Assets621.88
Total Income217.34
Profit After Tax32.71
NET Worth231.71
Reserves and Surplus175.94
Total Borrowing248.38
30 Sep 2024
Assets678.08
Total Income183.35
Profit After Tax23.94
NET Worth319.06
Reserves and Surplus263.36
Total Borrowing242.03
Trend chart₹ crore
KPIs
| KPI | Mar 31, 2024 |
|---|---|
| ROE | 23.60% |
| ROCE | 11.73% |
| Debt / Equity | 1.07% |
| RoNW | 23.60% |
| PAT Margin | 15.25% |
| Price to Book Value | 5.84 |
Valuation & shareholding
Pre-IPO EPS9.83
Post-IPO EPS13.86
Pre-IPO P/E39.77
Post-IPO P/E28.21
Promoter holding pre66.67%
Promoter holding post45.77%
Market cap₹1350.70 Cr.
Issue expenses
| Expense | Amount |
|---|---|
| Fees payable to the BRLMs | ₹22.32 Cr |
| Brokerage, selling commission, upload fees, processing fees and bidding charges for the Members of the Syndicate, Registered Brokers, SCSBs, RTAs and CDPs | ₹3.03 Cr |
| Fees payable to legal counsel, chartered accountants, and other intermediaries | ₹4.67 Cr |
| Listing fees, SEBI filing fees, book building software fees, depository charges and other regulatory expenses | ₹5.79 Cr |
| Printing and despatch of issue stationery expenses | ₹1.68 Cr |
| Advertising and marketing expenses for the Issue; and | ₹3.90 Cr |
| Miscellaneous | ₹0.80 Cr |
Registrar & lead managers
Registrar
MUFG Intime India Pvt.Ltd.Lead managers
- Ambit Pvt.Ltd.
Offer documents
Data is reconciled from multiple public IPO sources. Official exchange filings and offer documents remain the source of truth. Last verified 2026-08-24.